ArticleClinical and translational science2026
Exploring the Antimicrobial Efficacy of Mesenchymal Stem Cell Secretome Against Klebsiella pneumoniae in Urinary Tract Infections.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) has become a global health crisis, with Klebsiella pneumoniae (K. pneumoniae) emerging as a major driver of AMR and a leading cause of urinary tract infections (UTIs). Mesenchymal stem cell (MSC)-derived secretomes have gained attention for their antimicrobial properties. This study aimed to investigate the antibacterial activity of MSC-derived secretomes against urinary K. pneumoniae isolates. The secretomes derived from adipose tissue (AD-MSCs), bone marrow (BM-MSCs), and umbilical cord (UC-MSCs) were tested against 50 K. pneumoniae clinical strains isolated from urine, including extended-spectrum β-lactamase (ESBL)-, AmpC-, and carbapenem-resistant (CRE) strains. This secretome inhibited 68% of isolates overall, including 81.5% of K. pneumoniae (non-ESBL, non-AmpC, non-CRE), 46.7% of ESBL-, and 100% of AmpC-producing isolates, but showed no effect on CRE isolates. Genotypic analysis revealed that all ESBL-producing isolates (100%) harbored the blaSHV gene and expressed the fimH, wabG, uge, ureA, and entB virulence factors. These findings demonstrate, for the first time, the antibacterial potential of three distinct MSC secretome sources against K. pneumoniae, highlighting their promise as a novel adjunctive therapy for drug-resistant UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.